Medtronic Looks to Strengthen Spine with Osteotech Purchase
Executive Summary
Medtronic, struggling to hold onto its sizable share of the shrinking spinal market, made a bid for publicly traded Osteotech, a maker of a demineralized bone matrix agent that will broaden the company's regenerative product portfolio.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2010
Medical device financings during the third quarter of 2010 brought in $997 million, an increase of 82% from the second quarter's $548 million. While Q3 M&A activity was down slightly from last quarter - only 15 mergers were completed, compared with 18 in Q2 - more money was involved: an impressive $6.7 billion. The venture rounds for PacBio and Complete Genomics boosted late-stage VC money to $171 million in the third quarter, two-thirds of the entire amount for the in vitro diagnostics/research industry. Despite only five acquisitions closing during the third quarter, the M&A dollar volume for the IVD/research industry was just north of $2 billion.
Bioactive Technologies for Bone Replacement
The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.